PRSOR07 Presentation Time: 12:30 PM

Purpose: Optimal sequencing of high-dose rate (HDR) brachytherapy (BT) boost and whole pelvis intensity-modulated radiotherapy (IMRT) for definitive treatment of prostate cancer (PCa) is not defined. The prospective Timing of HDR brachytherapy with EBRT in Prostate Cancer (THEPCA) trial is ongoing to address this question. To our knowledge, we present the first report comparing early toxicity and disease outcomes for PCa patients treated with HDR-BT upfront vs. IMRT upfront combined with androgen deprivation therapy (ADT).